Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome
Ovarian Hyperstimulation Syndrome, Infertility, Female
About this trial
This is an interventional treatment trial for Ovarian Hyperstimulation Syndrome focused on measuring oocyte Maturity, Dual Trigger, Infertility, Female
Eligibility Criteria
Inclusion Criteria: They are between the ages of 18 and 40. They are undergoing IVF treatment with a GnRH antagonist protocol. During their current treatment cycle, they have at least one of the following risk factors for OHSS: Greater or equal to 13 follicles measuring at least 11 mm on the day of trigger. Serum estradiol levels greater or equal to 15,000 pmol/L on the day of trigger. Exclusion Criteria: They are using a GnRH agonist protocol (which is a contraindication to using a GnRH agonist trigger). They are planning on using a "dual trigger" (based on poor outcomes in a previous IVF cycle using a GnRH agonist trigger). They have a low ovarian reserve (AFC < 7 follicles or AMH < 10 pmol/L). They have had a previous failed GnRH agonist trigger. They have a known diagnosis of hypogonadotropic hypogonadism. They have had a previous adverse or allergic reaction to GnRH agonist in the past. They are using surgically retrieved sperm. They are undergoing treatment for fertility preservation (oncofertility patients). They have a history of recurrent implantation failure (defined as no clinical pregnancy after transfer of > 4 good-quality embryos). They have any congenital or acquire uterine anomalies distorting the uterine cavity. If serum estradiol levels are equal or exceed 28,000 pmol/L on the day of trigger
Sites / Locations
- Mount Sinai Hospital, Fertility Clinic
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Treatment Arm- Group A
Control Arm- Group B
A subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU).
A subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL) (sham-placebo).